Olfactory Outcomes of Dupilumab Treatment for Nasal Polyposis
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Chronic Rhinosinusitis With Nasal Polyps
- Olfactory Disorder
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: Single group 6 months treatment with Dupilumab.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04869436
- Collaborators
- Mount Sinai Hospital, Canada
- Investigators
- Principal Investigator: Leigh J Sowerby, MD, FRCS St. Joseph's Hospital London, ON, Canada
Get Well Soon